The CaRi-Heart platform helps detect both atherosclerosis and coronary inflammation based on routine cardiac CT scans. Credit: Caristo Diagnostics.

Caristo Diagnostics is piloting its new CaRi-Heart technology in National Health Service (NHS) hospitals in the UK.

The company is deploying the technology in these hospitals as part of the new coronary artery disease management pathway pilot.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Supported by NHS England, the new pilot is being carried out in five NHS trusts, comprising Liverpool Heart and Chest Hospitals NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, Milton Keynes University Hospital NHS Foundation Trust, the University Hospitals of Leicester NHS Trust and Royal Wolverhampton NHS Trust.

In accordance with NICE guidelines, the CaRi-Heart platform analyses cardiac computed tomography angiography (CCTA) scans of patients visiting Rapid Access Chest Pain Clinics.

This analysis enables healthcare professionals to improve their patient’s cardiac risk evaluation for optimising medical management.

Released for the UK and EU markets, the platform can identify both atherosclerosis (plaque) and coronary inflammation based on routine cardiac CT scans.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The CaRi-Plaquemodule, which is CaRi-Heart’s newest product component, is a web-based software medical device that helps trained operators analyse CCTA data to characterise and quantify coronary plaque components.

Furthermore, the module helps prepare a report that covers the physical characteristics of coronary plaque driven by artificial intelligence algorithms.

Through the patient-specific Fat Attenuation Index Score, the report of CaRi-Heart quantifies coronary inflammation.

The report also offers the CaRi-Heart Risk, which evaluates the overall eight-year risk of a fatal heart attack.

Caristo Diagnostics CEO Frank Cheng said: “Caristo and our clinical partners are excited about this groundbreaking clinical initiative supported by NHS England.

“We anticipate that this real-world implementation will pave the way for the CaRi-Heart technology to be broadly adopted both across the NHS and around the world.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact